SCHEMBL1250144

SCHEMBL1250144

O=C(Nc1ccccc1F)c1ccc2nc(-c3c(Cl)cccc3Cl)[nH]c2c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 3/20 0.69
▸ PRSS12 P56730 3/20 0.62
▸ HDAC6 Q9UBN7 4/20 0.52
▸ RAB9A P51151 4/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ KDR P35968 1/20 0.51
▸ NR2E3 Q9Y5X4 1/20 0.50
▸ NPC1 O15118 3/20 0.48
▸ MAPT P10636 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ ITGB1 P05556 1/20 0.47
▸ ITGA4 P13612 1/20 0.47
▸ ITGB7 P26010 1/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250109 0.90 DGAT1 (0.72) DGAT1PRSS12HDAC6RAB9AKMT2A
SCHEMBL1250958 0.87 DGAT1 (0.69) DGAT1PRSS12HDAC6RAB9ACYP3A4
SCHEMBL1249943 0.87 DGAT1 (0.69) DGAT1PRSS12HDAC6RAB9AKMT2A
SCHEMBL1251453 0.85 DGAT1 (0.66) DGAT1PRSS12HDAC6RAB9ACYP3A4
SCHEMBL1248743 0.85 DGAT1 (0.65) DGAT1HDAC6RAB9AKMT2AMEN1
SCHEMBL1249930 0.84 DGAT1 (0.85) DGAT1PRSS12HDAC6RAB9AKMT2A
SCHEMBL2361754 0.84 PRSS12 (0.56) DGAT1PRSS12RAB9AKMT2AMEN1
SCHEMBL1250649 0.84 DGAT1 (0.80) DGAT1RAB9AKDRNR2E3NPC1
SCHEMBL1251070 0.84 DGAT1 (0.80) DGAT1KDRNR2E3
SCHEMBL1251547 0.84 DGAT1 (0.84) DGAT1KMT2AKDRNR2E3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 — — US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 DGAT1 1/4885PRSS12 4183/4885HDAC6 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback